Royalty Pharma (RPRX) PT Raised to $51 at Goldman Sachs
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $59.09 +0.84%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 18 | New: 20
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 18 | New: 20
Join SI Premium – FREE
Goldman Sachs analyst Asad Haider raised the price target on Royalty Pharma (NASDAQ: RPRX) to $51.00 (from $45.00) while maintaining a Buy rating.
You May Also Be Interested In
- Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson Following Q2 Results
- Broadridge Financial (BR) PT Raised to $180 at UBS, Neutral Rating Maintained
- Harley-Davidson (HOG) PT Raised to $33 at DA Davidson Amid Progress on Back to Bricks Strategy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
